Taiwan health officials warn of respiratory infection risks and vaccine upgrades

Medical experts in Taiwan are highlighting the risks of respiratory infections, specifically Mycoplasma pneumoniae and Streptococcus pneumoniae.

Mycoplasma pneumoniae, often referred to as ‘walking pneumonia,’ is causing concern due to its ability to cause persistent coughing, high fever, and potential extra-pulmonary complications such as rashes, hepatitis, or myocarditis. Because this bacterium lacks a cell wall, common antibiotics like penicillin and amoxicillin are ineffective. Furthermore, rising antibiotic resistance in East Asia, linked to gene mutations, is complicating treatment for children.

Separately, health officials are emphasizing the importance of Streptococcus pneumoniae vaccination. While many citizens prioritize COVID-19 and influenza vaccines, the risk of invasive pneumococcal disease remains significant, particularly for those aged 19 to 64 who may overlook it.

To improve protection, Taiwan's Centers for Disease Control has upgraded its public vaccination program. As of August 10, new 20-valent and 21-valent pneumococcal vaccines are being provided to eligible groups, including seniors over 65 and high-risk individuals. These single-dose vaccines are intended to replace older multi-dose regimens, benefiting approximately 3.17 million people.